Schering-Plough Corp.

Dick Kogan is the former Chairman, President and CEO of Schering-Plough Corporation. Schering-Plough is a Fortune 500 company engaged in the discovery, manufacturing and marketing of pharmaceutical and consumer products throughout the world. Mr. Kogan currently serves as a Director of Colgate-Palmolive Company. The Bank of New York Company, Inc. He is a Trustee of New York University and the Saint Barnabas Corporation and Medical Center. He is also an Overseer of the Stern School of Business and a member of the Council on Foreign Relations.

Karl D. Salnoske is vice president and chief information officer of Schering-Plough Corporation. Salnoske is responsible for directing the planning, acquisition, development and operation of computer, telecommunication and information systems for all corporate and divisional offices. He is also responsible for establishing the technical infrastructure and setting strategic guidelines for use of information systems technology throughout the company. Salnoske joined the company in November 2004 from Adaptive Trade, where he was president and chief executive officer. Prior to this position, he served as general manager, software solutions, and as vice president, global services, at IBM. Throughout his career, Salnoske has held leadership positions with increasing responsibility at McKinsey & Co., Telenet, Xerox and Exxon. Salnoske holds a B.S. degree in electrical engineering from Virginia Polytechnic Institute in Blacksburg, Va., where he serves on the advisory board for the Department of Electrical and Computer Engineering.

Robert Bertolini is executive vice president and chief financial officer of Schering-Plough Corporation. Bertolini joined Schering-Plough in his present position in November 2003. He is responsible for building a dynamic global finance team that comprises key financial areas, including taxes, accounting, internal audits, financial asset management, external financial relations, investments for employee benefit plans, and risk management and insurance. Additionally, he has responsibility for global information technology and business development. In his previous role at PricewaterhouseCoopers, Bertolini managed the global pharmaceutical industry practice. He has extensive experience in audit, financial controls and corporate governance as well as in acting as a senior adviser to top management on financial and general business issues, including licensing and M&A transactions. Bertolini began his professional career at the former Coopers & Lybrand in 1983 and rose steadily through the company's professional ranks, serving blue-chip global clients in the pharmaceutical industry. Bertolini graduated with a B.A. degree in economics from Rutgers University. He is a Certified Public Accountant.

Dr. Spiegel is Senior Vice President, Medical Affairs and Chief Medical Officer at Schering-Plough Research Institute, the pharmaceutical research arm of Schering-Plough Corporation, a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its more than 30,000 people around the world. This company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com. He is chair of Schering-Plough's Clinical & Preclinical Safety Surveillance Committee (CPSSC). Prior to his current position, Dr. Spiegel was Senior Vice President, Clinical Research. He is also Adjunct Assistant Professor in the Department of Medicine at NYU Medical Center in New York, NY. Dr. Spiegel has published over seventy scientific papers and serves on the Board of Directors of Cancer Care, Inc., the Cancer Institute of New Jersey and the Leukemia Society of America. He has special research interest in biological approaches to cancer therapy. Dr. Spiegel received a B.A. at Yale University and M.D. at the University of Pennsylvania and completed a Fellowship in Medical Oncology at the National Cancer Institute before he joined Schering Corporation in 1983.

Bruce R. Reid is senior vice president, Global Business Operations, for the Global Pharmaceutical Business of Schering-Plough Corporation, a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its more than 30,000 people around the world. This company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com. Mr. Reid joined Schering-Plough in his present position in July 2003. He is responsible for managing the P & L for the US Pharmaceutical Business as well as providing operational management for Global Pharmaceutical Business finance and information technology. In addition he oversees the key support functions of the company's Global Business Operations unit, which include U.S. sales operations and distribution, global training, global planning and financial forecasting, global market research and strategic communications for GPB. Additionally, Mr. Reid has responsibility for managing the Warrick Pharmaceuticals generics and Diversified Products business. Mr. Reid has more than 20 years of experience in the pharmaceutical industry. He came to Schering-Plough from Pharmacia Corporation, where he served most recently as group vice president of global business operations, where he built a world class global operations function and shared joint responsibility for managing Pharmacia's $12 billion U.S. pharmaceutical business. He previously served as vice president, Business Planning and Control. He also held a number of positions in sales and marketing management with Wyeth-Ayerst Pharmaceuticals and A.H. Robins. Mr. Reid earned both a B.S. degree in biology and an M.B.A. degree in finance from the University of Michigan.

Ian McInnes, Ph.D., is senior vice president and president, Global Supply Chain (GSC), for Schering-Plough Corporation. McInnes joined Schering-Plough as senior vice president, Global Supply Chain, in May 2004. In his present position, he is responsible for the supply of products to Schering-Plough's customers worldwide, including human prescription medicines as well as animal health and consumer health care products. He leads the development and implementation of a global manufacturing strategy to integrate all manufacturing facilities worldwide, including those of Organon and Intervet. Additionally, he is responsible for the Company's global procurement activities. McInnes came to Schering-Plough from Watson Pharmaceuticals, Inc., where he held the position of executive vice president, Supply Chain. He previously was employed by Pharmacia Corporation as senior vice president, Global Supply, and was an elected officer. While with Pharmacia, McInnes was responsible for the quality and supply functions at 44 plants around the world. Having spent his entire career in the pharmaceutical industry, McInnes has held positions of increasing responsibility at GlaxoSmithKline, Baxter Healthcare and AstraZeneca. McInnes holds both a B.S. degree in manufacturing technology and manufacturing management and a Ph.D. degree in manufacturing engineering and systems from the University of Strathclyde in Glasgow, Scotland.

John B. Landis, Ph.D., is senior vice president, Pharmaceutical Sciences, for Schering-Plough Research Institute, the pharmaceutical research arm of Schering-Plough Corporation. Landis joined Schering-Plough in his present position in September 2003. In this role, he is developing and implementing strategies for Schering-Plough Research Institute's pharmaceutical sciences function, comprising analytical, chemical, pharmaceutical, biological, global clinical supplies and the compliance and R&D quality assurance organizations. Landis is responsible primarily for developing active pharmaceutical ingredients, clinical trial and commercial formulations, and associated clinical supplies, including transfer of technology, to facilitate the approval and commercial launch of quality drug and biologic products. Landis joined Schering-Plough from Pharmacia Corporation, where, as senior vice president, preclinical development, he led the global pharmaceutical sciences, drug metabolism and toxicology organizations. Previously, he was vice president, central nervous system (CNS) psychiatry, critical care and inflammation development, for Pharmacia & Upjohn. He also had been employed by the Upjohn Company, where he held positions of increasing responsibility in the areas of analytical research, quality assurance and quality control. Landis earned Ph.D. and M.S. degrees in analytical chemistry from Purdue University and a B.S. degree in chemistry from Kent State University.

Margriet Gabriel-Regis is senior vice president, Specialty Care Customer Group, for the Global Pharmaceutical Business of Schering-Plough Corporation, a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its more than 30,000 people around the world. This company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com. Ms. Gabriel-Regis joined Schering-Plough in September 2003. She is responsible for developing and directing the implementation of comprehensive global marketing and sales strategies for the company's specialty care products. She also is responsible for managing the U.S. specialty product P&L, as well as strategic marketing and shared P&L accountability with the country operations for each global franchise. Prior to joining Schering-Plough, Ms. Gabriel-Regis held the position of group vice president - hospital and specialty for Pharmacia Corporation, where she managed P&L in the U.S. market and globally across five therapeutic franchises. She had joined Pharmacia in 2000 as group vice president, hospital. Previously, she was employed by Rhone-Poulenc Rorer, where she held various leadership roles in strategic planning and marketing. Ms. Gabriel-Regis began her career at Lederle International, which subsequently merged with Wyeth. During the course of her 13 years there, she held a number of increasingly responsible positions in finance, sales, marketing and country management. Ms. Gabriel-Regis earned a B.A. degree, summa cum laude, from McMaster University, Hamilton, Ontario, Canada, and an M.B.A. degree in finance from Pace University, New York.

Peder K. Jensen, M.D., is executive vice president, global clinical development, for Schering-Plough Research Institute, the pharmaceutical research arm of Schering-Plough Corporation, a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its more than 30,000 people around the world. This company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com. Dr. Jensen is responsible for clinical development worldwide, including clinical research operations, and clinical quality and compliance. Dr. Jensen, who has had two tenures at Schering-Plough, first joined the company in 1991 as senior director, clinical research (allergy/central nervous system). He held positions of increasing responsibility, including that of vice president, clinical research (allergy/central nervous system), until 1998, when he left Schering-Plough to join British Biotech as development director and chief medical officer. In 1999, Dr. Jensen joined Chiron Corporation as corporate vice president, worldwide product development. He returned to Schering-Plough in 2002, at which time he assumed his present position. Dr. Jensen received his M.D. degree from the University of Copenhagen Medical School. He completed training in internal medicine and neurology at the University Clinic, Department of Hematology and Department of Neurology, Hvidovre Hospital in Copenhagen. He was awarded a research fellowship from the Danish Medical Research Council. Dr. Jensen has been published extensively. A registered M.D. in the European Union, Sweden and Norway, he is also a member of the Danish Medical Society, Danish Epilepsy Society, Danish Neurology Society and American Epilepsy Society.

Sean McNicholas is senior vice president, Cardiovascular Products and U.S. Sales, for the Global Pharmaceutical Business of Schering-Plough Corporation. McNicholas chairs the U.S. Executive Team charged with delivery of the U.S. sales and profit targets. In this role, he has day-to-day management responsibility for the U.S. sales group. On a global basis, McNicholas is responsible for the cardiovascular portfolio at Schering-Plough, namely INTEGRILIN, an injectable IIb/IIIa antiplatelet drug, and the cholesterol management therapies ezetimibe (ZETIA) and ezetimibe/simvastatin (VYTORIN), both part of a joint venture with Merck & Co., Inc., in Europe and the U.S. In Japan, McNicholas represents Schering-Plough with ezetimibe (ZETIA) as part of a joint venture with the Bayer Corp. In addition, McNicholas co-chairs the Cardiovascular and Metabolic Discovery and Development Team and leads commercial implementation plans for the corporation's pipeline projects. He is Schering-Plough's representative at PhRMA. McNicholas joined Schering-Plough in 2002 as vice president, Marketing, with responsibility for Schering-Plough's allergy, respiratory and dermatological franchises. He came to Schering-Plough from SYN.X, Pharma Inc., Toronto, Canada, where he served as president and CEO. Previously, he held various sales, marketing and strategic planning positions with Eli Lilly and Pharmacia Corporation. McNicholas holds a B.S. degree in environmental biology from Swansea University, Wales, Great Britain, and an M.S. degree in plant physiology from the University of Alberta, Canada.

Alex Kelly R.Ph. Group Vice President, Global Communications and Investor Relations Schering-Plough Corporation Kenilworth, New Jersey -------------------------------------------------------------------------------- Alex Kelly, R.Ph., is group vice president, Global Communications and Investor Relations, for Schering-Plough Corporation. Kelly was named to his current position in October 2007 and is responsible on a global basis for Corporate External and Internal communications, Product Communications and Investor Relations. He is also responsible for communications related to the company's three core customer segments: Human Prescription Pharmaceuticals, Consumer Health Care and Animal Health. He joined Schering-Plough in April 2004 as vice president of Investor Relations. Kelly has more than 18 years of experience in the pharmaceutical industry. Prior to joining Schering-Plough, Kelly was executive director of Investor Relations for Novartis Corporation. While at Novartis, he was based in Switzerland and focused on building relationships with European investors and analysts. Previously, Kelly was senior director of Investor Relations at Pharmacia Corporation. Prior to that assignment, he held a number of positions of increasing responsibility in Investor Relations and Sales at Pharmacia Corporation, Pharmacia & Upjohn and The Upjohn Company, where he began his career as a pharmaceutical sales representative. Kelly holds a B.S. degree in pharmacy from Purdue University in Indiana.

E. Kevin Moore is vice president and treasurer of Schering-Plough Corporation, a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its more than 30,000 people around the world. This company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

James R. Nelson is vice president, patents and trademarks and associate general counsel of Schering-Plough Corporation, a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its more than 30,000 people around the world. This company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

Jeff Berkowitz is group vice president, Global Market Access and U.S. Managed Markets, for Schering-Plough Corporation. In this role, Berkowitz leads Schering-Plough's market access activities worldwide for company products across the portfolio. He is also responsible for managed care sales and for marketing, developing and implementing all strategies, initiatives and operations for Schering-Plough's core brands in all managed markets within the U.S. Additionally, Berkowitz leads a team of pricing and reimbursement and health economists that provide support to country operations worldwide. Berkowitz, a licensed attorney with health care law expertise, joined Schering-Plough in 1998 as a senior commercial counsel in the Law department. Prior to joining Schering-Plough, Berkowitz was a health care attorney with the international firm of Proskauer Rose, specializing in health care mergers and acquisitions, fraud and abuse, licensing and corporate issues. Berkowitz graduated from Union College in 1988 with a B.A. in political science. He received a J.D. degree from Brooklyn Law School in 1992. He is a member of the Bar in New York and New Jersey.

John M. Carroll is vice president, Global Internal Audits, for Schering-Plough Corporation. He is responsible for directing the internal auditing activities of the company worldwide. Carroll joined Schering-Plough in his current position in July 2006. He is a member of the Operations Management Team and an elected officer of the company. Prior to joining Schering-Plough, Carroll was with American Standard Companies, where he was most recently vice president and general auditor as well as an elected officer. Prior to that, he worked at Bristol-Myers Squibb Company, holding a number of senior finance positions, and with Ernst & Young as a senior manager. Carroll is a Certified Public Accountant and holds a B.S. degree in accounting from St. John's University in New York.

Lisa W. DeBerardine is vice president, Strategic Planning & Financial Forecasting, for Schering-Plough Corporation. DeBerardine is responsible for the corporate planning and forecasting function and certain strategic projects. DeBerardine joined Schering-Plough in 1985 and since that time has held positions of increasing responsibility in Research, Pharmaceutical Operations and Investor Relations. She was most recently staff vice president, Investor Relations. Prior to joining Schering-Plough, DeBerardine held the position of research group leader for Chase Chemical Company. DeBerardine holds a B.S. degree from Rutgers University College of Pharmacy, and a master's in business administration, finance, from Rutgers University.

Steven H. Koehler is vice president and controller of Schering-Plough Corporation. Koehler joined Schering-Plough in March 2006 from The Medicines Company, where until his departure he served as senior vice president, chief financial officer and treasurer. During his career, Koehler held senior positions in the finance divisions at several pharmaceutical companies. He served as vice president and chief financial officer at Vion Pharmaceuticals. He also was vice president, Finance Americas, for the Knoll Pharmaceuticals Company, the U.S. pharmaceutical unit of BASF. While at BASF, he spent four years as vice president, global finance and controller, based in Germany. He also had divisional finance lead positions at Baxter International Inc. Koehler, a Certified Public Accountant, began his career in the auditing profession with Arthur Andersen LLP. He holds a B.A. from Duke University, Durham, N.C., and an M.B.A. from Northwestern University, Evanston, IL.

Dr. Sumant Ramachandra brings nearly 20 years of healthcare experience and strong leadership abilities to his role as senior vice president, Research & Development (R&D) and Medical Affairs, and chief scientific officer of Hospira, Inc. Prior to joining Hospira in July 2008, Dr. Ramachandra spent much of his career leading scientific advancements for some of the industry's largest pharmaceutical companies, including Merck, Pharmacia, Pfizer and Schering-Plough. As an R&D business leader, Dr. Ramachandra set in motion several therapy programs that would benefit patients living with cancer -- such as Camptosar® (irinotecan hydrochloride injection) and Aromasin® (exemestane tablets) at Pfizer, and Temodar® (temozolomide capsules) at Schering-Plough. He was responsible for formulating innovative strategies and executing R&D plans that resulted in successful U.S. Food and Drug Administration (FDA) approvals. Dr. Ramachandra's award-winning work is also widely recognized through publications. He has participated in a multitude of scientific studies on tumor cell biology and immunology as well as authoring book chapters about basic cell biology and oncology. Additionally, he has filed several product patents for various cancer treatments and the use of antibodies in cancer therapy. He earned a bachelor's degree in biochemistry from Rutgers University, graduating with high honors. Dr. Ramachandra then pursued a combined M.D./Ph.D. degree from the University of Medicine and Dentistry - New Jersey Medical School, earning the University's Medal of Excellence and subsequently conducting his residency at the Harvard-affiliated Massachusetts General Hospital. He is now nearing completion of a master's of business administration at Wharton Business School.

Susan Ellen Wolf is corporate secretary, associate general counsel and vice president-Governance of Schering-Plough Corporation. Wolf and her team are responsible for providing legal counsel with respect to securities law, corporate governance (including the annual meeting of shareholders), director/executive compensation, corporate law, financings and employee compensation/benefits. The director-Strategic Affairs is a member of her office and has responsibility for the company's Social Issues Program. Wolf joined Schering-Plough in 2002 as senior director, Corporate Law, and in 2003, was appointed staff vice president, Corporate Law. She was appointed Corporate Secretary in May 2004, named vice president-Corporate Governance in 2005 and became a member of the Operations Management Team in 2007. Prior to joining the company, Wolf held in-house positions at Contel Corporation (now part of Verizon), Baltimore Gas and Electric Company (now Constellation Energy Group), The Coca-Cola Company and Delta Airlines, Inc. Wolf was recognized by the Securities and Exchange Commission (SEC) for her work in the plain English program. She has served as chair of the Society of Corporate Secretaries and Governance Professionals; chair of the Society's Securities Law Committee; and a member of the Board of the Council of Institutional Investors. She is vice chairman of the Securities, Commodities and Exchanges Subcommittee of the American Bar Association Section on Administrative Law and is on the advisory board of the SEC Historical Society. She is also a member of the International Corporate Governance Network. Wolf earned a B.A. degree, with honors, in sociology from Emory University, Atlanta, Ga., and a J.D. degree from George Washington University, Washington, D.C. She is a member of the Maryland and Georgia bars.

Dr. Kornberg has been a director since April of 1991. He is a distinguished author and researcher who was chairman and founder of the Department of Biochemistry at the Stanford University School of Medicine. Dr. Kornberg received the Nobel Prize in 1959 for his discovery of the enzymatic synthesis of DNA. His present research is on the genetics, biochemistry, physiology and clinical relevance of inorganic polyphosphate. He is the author of "DNA Replication," one of the basic textbooks of biochemistry. Dr. Kornberg was a founder and is a member of the Boards of Scientific Advisors of DNAX, now a wholly owned subsidiary of Schering-Plough Corporation, and Regeneron Pharmaceuticals, Inc., a biotechnology company focused on neurobiology, and is a member of the Board of Scientific Advisors of Maxygen, Inc., a biotechnology company focused on molecular evolution technology.

Brenda S. "Sue" Fulton is a 1980 graduate of the US Military Academy with the first class to admit women. She served for five years in the Signal Corps, as a company commander and staff officer in Germany. After leaving the Army, Sue worked in brand management at Procter & Gamble and Church & Dwight; she also took two years to work in parish renewal programs for the Archdiocese of New York. Sue is currently a brand director of OTC Brands for Schering-Plough and lives in North Plainfield, NJ, with her partner Penny Gnesin. Sue serves as an at-large board member for Knights Out.

Gary L. Riddle, MPA., is a Senior Government Affairs Manager for Schering-Plough Corporation. While serving in this capacity for Schering-Plough since 2003, Gary has maintained government affairs responsibilities for the Mid-Atlantic area, including the states of Virginia, Maryland, Delaware, and the District of Columbia. In his current capacity, Gary also assists with the coordination of advocacy campaigns within the profession of pharmacy and other pertinent health professional organizations. Prior to joining Schering-Plough, Gary served as a state government affairs manager for the American Society of Consultant Pharmacists from 2000-2003 and worked as a fundraiser for Inova Health Systems in Northern Virginia from 1998-2000. His educational background includes a BS in Healthcare Administration from James Madison University and a Master's of Public Administration from The George Washington University.

Dr. Barnett is a successful drug development executive who brought four drugs to the marketplace during his tenure at Schering-Plough, two of which were blockbusters. His career was spent in Drug Discovery, where he led the effort that resulted in the discovery of Claritin, a non-sedating antihistamine that was Schering-Plough's leading product and the fifth leading drug, based on sales, in the world. Dr. Barnett managed a discovery program that led to Doral, a sedative-hypnotic that was out-licensed by Schering. Dr. Barnett and his colleagues made a major contribution to the field of dopamine receptors by discovering and developing the first D1 receptor antagonists. He managed the discovery program that led to Zetia, a novel cholesterol-lowering agent that was introduced to the market in November 2002, and to Clarinex, the successor to Claritin. In 1994, Dr. Barnett assumed the duties of Vice President of Technology Acquisition and External Collaborations with the objective of facilitating all areas of drug discovery based collaborations for SPRI.

Bin Chen is currently a senior researcher for Schering-Plough in New Jersey. He started his research career in 1990 when he graduated from Department of Applied Chemistry, University of Science and Technology of China, and joined Research Center for Eco-Environmental Sciences (RCEES), Chinese Academy of Sciences. He got a Master's degree in Environmental Chemistry during his stay in RCEES. In 1996, he moved to the United States and studied at University of Minnesota. He got his Ph.D. degree in Chemistry from University of Minnesota in 2001. He then conducted postdoctoral studies at University of Minnesota and University of Kansas before he joined Schering-Plough in 2003. Bin Chen became a Christian in 1997 and was baptized at Twin Cities Chinese Christian Church (TCCCC). He was one of the founders of New Life Fellowship in TCCCC, a fellowship mainly serving students and scholars from mainland China. He served passionately as the co-ordinator of NLF before he left Minnesota in 2002. For a long time Bin Chen has had the burden to serve his motherland with his knowledge and Christian worldview. He is especially interested in introducing and developing "clean technologies" that are essential for China to achieve "sustainable development." He has been seeking God's leading towards this direction. He is excited about the vision of SPUC and will be involved in designing academic programs for SPUC.

Mike Zampella was an Information Technology manager with Lucent Technologies in Murray Hill, New Jersey until his recent retirement. Mike managed the installation and maintenance of remotely installed systems and is involved in Year 2000 compliance for those systems. Mike has 20 years of Records Management experience including Forms Management, microfilm/microfiche operations manager, and records management systems manager. Mike is now with Schering-Plough Corp. as a Senior Records Analyst. He is responsible for all the Corporate Center Records Retention schedules and also serves as web content manager for the Records Management portion of the Schering website. He has served on the Northern New Jersey ARMA Board of Directors holding many positions including President. He was Chapter Member of the year in 1990 and 2001 and won the Website of the year award in 2000. Mike is currently the Webmaster of the Chapter's web site - www.armannj.org.

Arthur F. Weinbach currently serves as executive chairman of Broadridge Financial Solutions, Inc., a leading full-service outsourcing provider to the global financial industry. In addition to Broadridge and CA, Arthur also serves on the board of Schering-Plough Corp. and is on the board of trustees for New Jersey SEEDS, an academic and leadership program for high-achieving, low-income youth. Previously, Arthur spent 28 years at Automatic Data Processing, Inc. (ADP), where he served in senior executive roles with increasing levels of responsibility. Until November 2007, Arthur served as ADP's non-executive chairman, from 1998-2006 as chairman and CEO, and from 1996-1998 as president and CEO. Earlier, Arthur was a partner in the accounting firm of Touche Ross & Co., which is now part of Deloitte Touche Tohmatsu. Arthur has also served on the boards of ADP, First Data Corporation, Inc., Health Plan Services Corp. and Decision One.

Carl E. Mundy, Jr. Director Carl E. Mundy, Jr., 72, director since 1998. Retired General, U.S. Marine Corps. Commandant of the Marine Corps from 1991 to 1995. President and Chief Executive Officer of the World USO from 1996 to 2000. Member of the Advisory Committee to the Comptroller General of the United States from 2001 to 2007. Chairman of the Marine Corps University Foundation since 1995. Director of Schering-Plough Corporation.

Ms. Neese has over 20 years of consulting and industry experience. She is currently the Vice President for Strategic Partnerships at McKesson Corporation, where she specializes in relationship and business development. Prior to joining McKesson, Ms. Neese was a senior consultant in the eConsulting Group at Digineer, a technology and management consulting firm. In addition to providing consultation about cost/quality programs and web-based virtual staff offerings, Ms. Neese represented Digineer at educational forums, eHealth symposia and medical society meetings. In her previous position as vice president of Corporate Services at Phycor, Inc., she had fiscal and operational responsibility for enterprise-wide initiatives including Internet and e-commerce strategies for both the clinical delivery and the physician practice management sectors. Ms. Neese helped lead the rapid growth of the company from an organization with six clinics and 300-hundred physicians to a $1.4 billion organization with 55 clinics, 26 IPAs, and 26,000 physicians in seven years. Helen Neese studied at the University of Missouri where she earned both her bachelor's and master's degree. She sits on advisory boards for AstraZeneca, Glaxo Wellcome, MGMA, Merck & Co., Ofstead & Associates, Organon, Roche Laboratories, Schering Plough, Searle Pharmaceuticals, TAP Pharmaceuticals, and Bayer Pharmaceuticals. Helen has also served as chairman of the Vanderbilt University Center for Health Services.

Nicholas J. Hart has joined Emisphere Technologies, Inc. as vice president of strategy and development. In this capacity, Mr. Hart will be responsible for the planning and commercial development aspects of the company's Eligen technology. Mr. Hart joins the company with more than 16 years of commercial experience in the pharmaceutical industry. Most recently, he was leader of the Contraception Therapy Area and a member of the corporate executive leadership team for Organon, recently acquired by Schering Plough.